CGP 11130

Top Quality 4-Amino-3- (4-fluorophenyl) Butyric Acid Manufacturer CAS No. 52237-19-1

Item Name: 4F-Phenibut
CAS NO.:  52237-19-1
Apparence:White Powder
Place of Origin: China (Mainland)
Assay:No less than 99%
Packaging Details:100g,1kg/bag, 25kg/drum

Details :


Appearance:Solid powder

Purity:>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490

MedKoo Cat#: 524609 
Name: Cgp 11130 
CAS#: 52237-19-1 
Chemical Formula: C10H12FNO2 
Exact Mass: 197.08521 
Molecular Weight: 197.21 
Elemental Analysis: C, 60.90; H, 6.13; F, 9.63; N, 7.10; O, 16.23

Chemical Information

Technical Information

Biochemical Activity

F-Phenibut (Fluorophenibut) is a several-fold more potent derivative of Phenibut. Phenibut is an atypical anxiolytic and nootropic compound structurally similar to the well known inhibitory neurotransmitter GABA, as well as to baclofen (β-(4-chlorophenyl)-GABA) and pregabalin (β-isobutyl-GABA)[1]. Phenibut was originally thought to act solely as a selective GABAB receptor agonist, similar to its much more potent relative baclofen, but has more recently been found to additionally act with somewhat higher affinity as an inhibitor of α2δ subunit-containing voltage-gated calcium channels, a mechanism of action shared with gabapentin and pregabalin.[2]

Phenibut is known to have a wider spectrum of effects than baclofen; for example Phenibut has been found to be more effective as a nootropic and neuroprotective compound than baclofen[2],[3], while baclofen has a more narrowly focused spectrum of effects and anecdotally shows a reduced tendency to induce habituation or tolerance to its effects upon chronic daily administration[4].

Preliminary (unpublished) research tentatively suggests that F-Phenibut (Fluorophenibut) has a behavioral potency of approximately five to tenfold higher than Phenibut in vivo, with approximately sixfold higher affinity as a GABAB agonist than Phenibut[5], but may also retain comparable affinity and inhibitory efficacy at α2δ subunit-containing voltage-gated calcium channels, making F-Phenibut unique as an evenly balanced ligand for these two binding sites. As an intermediary between Phenibut and baclofen, these findings hint at the potential promise that this p-fluoro relative of Phenibut might retain the broader nootropic, anxiolytic, and mood elevating characteristics of Phenibut, while simultaneously partially sharing the relatively reduced tolerance inducing properties of its p-chloro relative baclofen.